This company listing is no longer active
4DE Stock Overview
A biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BiVictriX Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.16 |
| 52 Week Low | UK£0.081 |
| Beta | -0.73 |
| 11 Month Change | -28.42% |
| 3 Month Change | -25.75% |
| 1 Year Change | -33.67% |
| 33 Year Change | -51.93% |
| 5 Year Change | n/a |
| Change since IPO | -60.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DE | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 20.6% | -1.1% | 1.1% |
| 1Y | -33.7% | -18.8% | 7.2% |
Return vs Industry: 4DE underperformed the German Biotechs industry which returned -17.3% over the past year.
Return vs Market: 4DE underperformed the German Market which returned 3.9% over the past year.
Price Volatility
| 4DE volatility | |
|---|---|
| 4DE Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4DE's share price has been volatile over the past 3 months.
Volatility Over Time: 4DE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 17 | Tiffany Thorn | www.bivictrix.com |
BiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia.
BiVictriX Therapeutics plc Fundamentals Summary
| 4DE fundamental statistics | |
|---|---|
| Market cap | €9.79m |
| Earnings (TTM) | -€3.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs 4DE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DE income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£2.67m |
| Earnings | -UK£2.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4DE perform over the long term?
See historical performance and comparison